Primary and secondary angiosarcomas: a comparative single-center analysis

Clinical Sarcoma Research

Bernd Kasper¹  Peter Hohenberger¹  Franka Menge¹  Thorsten Hillenbrand¹ 

[1] Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany

关键词: Outcome;    Targeted therapy;    Chemotherapy;    Secondary angiosarcoma;    Primary angiosarcoma;   

Others  :  1206095
DOI  :  10.1186/s13569-015-0028-9

 received in 2015-02-12, accepted in 2015-04-14,  发布年份 2015

【 摘 要 】

Background

Angiosarcomas (AS) are rare vascular malignancies. They are subdivided into primary (PAS) and secondary angiosarcomas (SAS). The objective was to compare the characteristics of AS subtypes.

Methods

Eighteen PAS and ten SAS patients treated at our institution between 2004 and 2012 were included in this study.

Results

Median age of PAS and SAS patients was 52.9 and 64.2 years, respectively (p = 0.1448). The percentage of women was 27.8% for PAS, but 80.0% for SAS (p = 0.0163). While PAS occurred throughout the body, the majority of SAS arose from the breast (p = 0.0012). All SAS were radiation-induced with a median latency of 7.7 years. The majority of patients with PAS and SAS underwent surgery as primary or recurrence treatment (p > 0.95). Local recurrence was developed by 27.8% of PAS and 50.0% of SAS (p = 0.4119). 61.1% of PAS metastasized, but only 40.0% of SAS (p = 0.4328). Median overall survival for PAS and SAS was 19 and 57 months, respectively (p = 0.2306).

Conclusion

Radical surgery remains the mainstay of both primary and recurrence treatment. SAS show a high local recurrence rate, while PAS tend towards developing early metastases. Overall, prognosis is poor for both groups.

【 授权许可】

   
2015 Hillenbrand et al.

【 图 表 】

Figure1.

【 参考文献 】

• [1]Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D et al.. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001; 91:1914-1926.
• [2]Weiss SW, Goldblum JR. Malignant vascular tumors. In: Enzinger and Weiss’s soft tissue tumors. 4th ed. Weiss SW, Goldblum JR, editors. Mosby, St. Louis; 2001: p.917-954.
• [3]Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol. 2008; 32:1896-1904.
• [4]Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD et al.. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013; 20:1267-1274.
• [5]Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G. Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat. 2012; 132:1081-1088.
• [6]Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010; 11:983-991.
• [7]Hung J, Hiniker SM, Lucas DR, Griffith KA, McHugh JB, Meirovitz A et al.. Sporadic versus radiation-associated angiosarcoma: a comparative clinicopathologic and molecular analysis of 48 cases. Sarcoma. 2013.
• [8]Guo T, Zhang L, Chang NE, Singer S, Maki RG, Antonescu CR. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom Cancer. 2011; 50:25-33.
• [9]Manner J, Radlwimmer B, Hohenberger P, Mossinger K, Kuffer S, Sauer C et al.. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010; 176:34-39.
• [10]Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA et al.. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007; 14:1953-1967.
• [11]Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S et al.. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007; 18:2030-2036.
• [12]Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005; 11:241-247.
• [13]Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996; 77:2400-2406.
• [14]Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS et al.. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003; 98:1716-1726.
• [15]Fata F, O’Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP et al.. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999; 86:2034-2037.
• [16]Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E et al.. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012; 118:3330-3336.
• [17]Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S et al.. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008; 26:5269-5274.
• [18]Maki RG, D’Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD et al.. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27:3133-3140.
• [19]Buehler D, Rice SR, Moody JS, Rush P, Hafez GR, Attia S et al.. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014; 37:473-479.
• [20]Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD et al.. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010; 251:1098-1106.
• [21]Strobbe LJ, Peterse HL, van Tinteren H, Wijnmaalen A A, Rutgers EJ. Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat. 1998; 47:101-109.
• [22]De Smet S, Vandermeeren L, Christiaens MR, Samson I, Stas M, Van Limbergen E et al.. Radiation-induced sarcoma: analysis of 46 cases. Acta Chir Belg. 2008; 108:574-579.
• [23]Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg. 2002; 184:356-358.
• [24]Seinen JM, Styring E, Verstappen V, Vult von Steyern F, Rydholm A, Suurmeijer AJ et al.. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol. 2012; 19:2700-2706.
• [25]Ge Y, Ro JY, Kim D, Kim CH, Reardon MJ, Blackmon S et al.. Clinicopathologic and immunohistochemical characteristics of adult primary cardiac angiosarcomas: analysis of 10 cases. Ann Diagn Pathol. 2011; 15:262-267.
• [26]Morgan MB, Swann M, Somach S, Eng W, Smoller B. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004; 50:867-874.
• [27]Jallali N, James S, Searle A, Ghattaura A, Hayes A, Harris P. Surgical management of radiation-induced angiosarcoma after breast conservation therapy. Am J Surg. 2012; 203:156-161.
• [28]Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC et al.. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer. 2012; 118:2682-2692.
• [29]Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005; 104:361-366.
• [30]Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C et al.. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012; 17:260-266.
• [31]Lindet C, Neuville A, Penel N, Lae M, Michels JJ, Trassard M et al.. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Eur J Cancer. 2013; 49:369-376.
• [32]Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW et al.. Angiosarcoma of the breast. Cancer. 2005; 104:2682-2688.
• [33]Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, Oosterhuis JW et al.. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003; 39:64-69.